Myelodysplastic Syndromes: The FDA Grants Fast Track Designation for Eltanexor
source: pixabay.com

Myelodysplastic Syndromes: The FDA Grants Fast Track Designation for Eltanexor

  Karyopharm Therapeutics, a pharmaceutical company focusing on novel cancer therapies, has issued a statement via PR Newswire that the FDA has granted regulatory designations to eltanexor, Karyopharm’s Selective Inhibitor…

Continue Reading Myelodysplastic Syndromes: The FDA Grants Fast Track Designation for Eltanexor

FDA Orphan Drug Designation Awarded to a Myelodysplastic Syndromes Investigative Therapy

Karyopharm Therapeutics has just announced that Eltanexor, their investigative therapy for myelodysplastic syndromes (MDS), has been given Orphan Drug Designation by the FDA. This designation means that the FDA believes…

Continue Reading FDA Orphan Drug Designation Awarded to a Myelodysplastic Syndromes Investigative Therapy
Recent Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes
https://unsplash.com/photos/8rj4sz9YLCI

Recent Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes

An article in PubMed dated October 8, 2021 outlines immune therapies treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients. Both cancers are hematologic malignancies that begin in the…

Continue Reading Recent Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes

The MDS Foundation’s 2022 Webinars: Focus on Understanding Clinical Trials and How to Identify the Right One for You

  • Post author:
  • Post category:

Webinar: Focus on Understanding Clinical Trials and How to Identify the Right One for You January 22, 2022 with Andrew M. Brunner, MD, Massachusetts General Hospital, Assistant Professor of Medicine,…

Continue Reading The MDS Foundation’s 2022 Webinars: Focus on Understanding Clinical Trials and How to Identify the Right One for You
A New Prediction Model Improves Accuracy in Determining the Probability of MDS Patients’ Survival
source: pixabay.com

A New Prediction Model Improves Accuracy in Determining the Probability of MDS Patients’ Survival

The outcome of myelodysplastic syndrome (MDS) varies. The disease can lie dormant for decades, or it can become fatal in a matter of months. According to a recent article in…

Continue Reading A New Prediction Model Improves Accuracy in Determining the Probability of MDS Patients’ Survival